| Company Overview | |
OcuSciences
Inc. was founded by Victor Elner, M.D., Ph.D. and Howard Petty, Ph.D. at the University of Michigan’s
Kellogg Eye Center
in order to develop and commercialize the OcuMet™ line of ocular metabolic
imaging products. Retinal metabolic analysis (RMA) is a novel technique that allows detection of certain eye diseases several
years earlier than current clinical methods.
The most significant impact of the The OcuMet™ products on current
healthcare practice is in the early detection and monitoring of diabetes. According to Centers for Disease Control (CDC)
statistics, diabetes affects 24 million Americans, one third of which are
unaware they have the disease. Even more
alarming are the 57 million pre-diabetic Americans, 10% of which will develop
diabetes each year. With
our products, we will be able to detect disease early, before
irreversible damage has occurred, in order to implement treatment and
help save millions of people's eyesight. Once diagnosed with
disease, our technology will help monitor disease progression and
mitigation by treatment.
OcuSciences Inc. is an
innovative company, taking the next step forward in improving healthcare and
the quality of life. |
| | |
| |
|
